Objectives
To determine the prevalence and spectrum of mutations and genotype phenotype relationships in the largest hypertrophic cardiomyopathy (HCM) cohort to date and provide an easy, clinically applicable phenotype-derived score that provides a pretest probability for a positive HCM genetic test.
Patients and Methods
Between 1999 and 2007, 1053 unrelated patients with the clinical diagnosis of HCM (60% male, age at diagnosis 44.4 ± 19 years) had HCM genetic testing for the HCM-associated myofilament genes. Phenotyping was performed by review of electronic medical record.
Results
Overall, 359 patients (34%) were genotype positive for a putative HCM associated mutation in ≥ 1 HCM-associated gene. Univariate and multivariate analyses demonstrated echocardiographic reverse curve morphology, age at diagnosis < 45 years, MLVWT ≥ 20 mm, family history of HCM, and family history of SCD to be positive predictors of positive genetic test while hypertension was a negative predictor. A score, based on the number 6 predictors of a positive genetic test, predicted a positive genetic test ranging from 6% when only hypertension was present to 80% when all 5 positive predictor markers were present.
Conclusions
In this largest HCM cohort published to date, the overall yield of genetic testing was 34%. Although all patients were diagnosed clinically with HCM, the presence or absence of six simple clinical/echocardiographic markers predicted the likelihood of mutation-positive HCM. Phenotype-guided genetic testing with the use of the Mayo HCM Genotype Predictor score provides an easy tool for an effective genetic counseling session.